Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 34
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Psychol Med ; 34(1): 169-72, 2004 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-14971638

RESUMO

BACKGROUND: In situations of chronic stress vasopressin plays an important role in regulating the hypothalamic-pituitary adrenal axis. The aim of the current study was to investigate the role of anterior pituitary vasopressin V3 receptors in maintaining the hypercortisolism seen in melancholic depression. METHOD: Fourteen patients with major depression and 14 age- and sex-matched healthy comparison subjects were recruited. Desmopressin (ddAVP) 10 microg was given intravenously and ACTH and cortisol release was monitored for 120 min. RESULTS: The mean +/- S.E.M. ACTH response in the depressives was 28.4 +/- 4.3 ng/l and in the healthy subjects was 18.8 +/- 4.9 ng/l (P = 0.04). The mean +/- S.E.M. cortisol response in the depressives was 261.8 +/- 46.5 nmol/l and in the healthy subjects was 107.3 +/- 26.1 nmol/l (P < 0.01). CONCLUSIONS: Patients with major depression have augmented ACTH and cortisol responses to desmopressin indicating enhanced V3 responsivity.


Assuntos
Hormônio Adrenocorticotrópico/sangue , Hormônio Liberador da Corticotropina/farmacologia , Desamino Arginina Vasopressina/farmacologia , Transtorno Depressivo Maior/metabolismo , Hidrocortisona/sangue , Receptores de Vasopressinas/efeitos dos fármacos , Hormônio Adrenocorticotrópico/efeitos dos fármacos , Adulto , Grupos Controle , Feminino , Humanos , Sistema Hipotálamo-Hipofisário/metabolismo , Masculino , Pessoa de Meia-Idade , Sistema Hipófise-Suprarrenal/metabolismo , Receptores de Vasopressinas/sangue
2.
Am J Gastroenterol ; 97(8): 1937-40, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12190157

RESUMO

OBJECTIVE: Acetylcholine plays a central and peripheral role in regulating gastric motility. In the hypothalamus, it is a key neuroendocrine modulator; acting through somatostatin, it brings about the release of growth hormone (GH). We measured hypothalamic cholinergic receptor sensitivity in patients with nonulcer dyspepsia (NUD) by examining GH release in response to cholinergic challenge. METHODS: Forty patients with NUD and 40 healthy comparison subjects were administered pyridostigmine (the acetylcholinesterase inhibitor, 120 mg), and GH release over a 3-h period was monitored. RESULTS: Calculating response as the maximum GH relative to baseline (delta GH), the mean +/- SEM response in the patients was 11.9 +/- 1.9 U/L and in the healthy subjects 6.7 +/- 0.7 mU/L (t = 2.1, df = 78, p = 0.03). Helicobacter pylori status had no appreciable impact on GH response with H. pylori-positive patients having a mean response of 10.5 +/- 2.1 mU/L and negative patients a mean response of 13.2 +/- 3.4 mU/L. Overall, patients with NUD release more GH in response to pyridostigmine challenge than healthy subjects. CONCLUSIONS: Patients with NUD may have a pathophysiological disturbance involving central cholinergic systems.


Assuntos
Inibidores da Colinesterase/farmacologia , Dispepsia/fisiopatologia , Hormônio do Crescimento/metabolismo , Brometo de Piridostigmina/farmacologia , Adulto , Análise de Variância , Área Sob a Curva , Estudos de Casos e Controles , Distribuição de Qui-Quadrado , Dispepsia/microbiologia , Feminino , Fase Folicular , Hormônio do Crescimento/sangue , Infecções por Helicobacter/complicações , Infecções por Helicobacter/diagnóstico , Helicobacter pylori , Humanos , Hipotálamo/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Taxa Secretória/efeitos dos fármacos
3.
Aliment Pharmacol Ther ; 15(10): 1613-8, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11564001

RESUMO

BACKGROUND: Dyspepsia is a common symptom for which an organic cause is found in only 40% of patients. When no cause is apparent and the dyspepsia is considered to be idiopathic, a diagnosis of non-ulcer dyspepsia is made. The pathophysiology of non-ulcer dyspepsia is poorly understood and numerous theories have been put forward, including a theory of enhanced central serotoninergic receptor sensitivity. AIM: To determine the sensitivity of serotonin receptors in non-ulcer dyspepsia. METHODS: Using a randomized, double-blind, placebo-controlled design, we compared buspirone (a serotonin type 1a partial agonist)-stimulated prolactin release in 50 patients and 59 healthy comparison subjects. Buspirone, 30 mg, or matching placebo was administered on two separate occasions and prolactin release over 180 min was monitored. Patients and healthy subjects received both treatments in random order, 1 week apart. RESULTS: Overall, patients with non-ulcer dyspepsia had greater prolactin release in response to the buspirone challenge than the healthy comparison subjects, with differences most significant at 90 min following the challenge. Enhancement occurred in patients both with and without Helicobacter pylori infection. Female subjects, both patients and healthy volunteers, showed a greater response to buspirone than male subjects, and the augmentation of response observed in male and female patients was greater in females. CONCLUSIONS: Patients with non-ulcer dyspepsia have enhanced central serotoninergic responses and such responses are independent of H. pylori infection. Blockade of such receptors might be an appropriate therapeutic strategy.


Assuntos
Buspirona/farmacologia , Dispepsia/metabolismo , Prolactina/sangue , Agonistas do Receptor de Serotonina/farmacologia , Adulto , Método Duplo-Cego , Dispepsia/sangue , Dispepsia/tratamento farmacológico , Dispepsia/microbiologia , Feminino , Infecções por Helicobacter/complicações , Infecções por Helicobacter/epidemiologia , Helicobacter pylori/isolamento & purificação , Humanos , Masculino , Pessoa de Meia-Idade , Receptores de Serotonina/efeitos dos fármacos , Receptores de Serotonina/metabolismo
4.
Psychoneuroendocrinology ; 26(7): 751-6, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11500255

RESUMO

Buspirone is known to stimulate prolactin release. Clinical studies (e.g. in chronic fatigue syndrome) suggest that the response may be influenced by baseline cortisol levels. We conducted a double-blind placebo-controlled study to examine the relationship between the prolactin response to buspirone challenge and baseline cortisol level. Fifty healthy volunteers took part in the study. Buspirone was found to consistently elevate PRL levels above those seen following placebo administration. The PRL response as measured by area under the curve was highly correlated with the baseline cortisol level.


Assuntos
Buspirona/farmacologia , Hidrocortisona/farmacologia , Prolactina/metabolismo , Agonistas do Receptor de Serotonina/farmacologia , Adulto , Método Duplo-Cego , Feminino , Humanos , Hidrocortisona/sangue , Masculino , Pessoa de Meia-Idade , Prolactina/sangue , Caracteres Sexuais
5.
Curr Diab Rep ; 1(3): 208-15, 2001 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-12643201

RESUMO

Distal sensory polyneuropathy is a common and unpleasant complication of diabetes mellitus. It is the main initiating factor for foot ulceration. The increasing prevalence of diabetes has important associated health implications, both in terms of morbidity and mortality, and results in the consumption of scarce medical resources. Identification of somatic neuropathy in clinical practice is therefore important for targeted educational and other interventions. In this article, we describe methods for detecting somatic neuropathy in clinical practice and highlight those tests that are proven to be predictors of foot ulceration. The approach for detecting and characterizing somatic neuropathy for clinical trials, however, differs significantly. These methods must ideally have high levels of reproducibility, sensitivity, and specificity. Currently, several neurophysiologic tests are employed in clinical trials in order to accurately characterize diabetic neuropathy. The recent introduction of the computer-assisted programs for the measurement of sensory modalities for clinical trials has been a major advance. Due to their invasive nature and associated morbidity, nerve biopsy studies are no longer used in clinical trials. Recently, using magnetic resonance imaging (MRI), significant spinal cord atrophy has been demonstrated in established neuropathy. If this observation proves to be an early feature, then a relatively rapid, noninvasive MRI technique may be used in the future to characterize diabetic neuropathy.


Assuntos
Ensaios Clínicos como Assunto/métodos , Neuropatias Diabéticas/diagnóstico , Neuropatias Diabéticas/tratamento farmacológico , Humanos , Imageamento por Ressonância Magnética , Testes Neuropsicológicos
6.
Psychiatry Res ; 97(1): 21-8, 2000 Dec 04.
Artigo em Inglês | MEDLINE | ID: mdl-11104854

RESUMO

Abnormalities of the production of dehydroepiandrosterone (DHEA), the adrenal androgen, have been linked with disorders such as obesity and psychological disorders such as major depression. Adrenocorticotropin (ACTH) is the primary stimulant of DHEA, and cortisol, from the adrenal. We chose to examine the DHEA and DHEA/cortisol response to the novel low-dose ACTH test in healthy subjects and a cohort with chronic fatigue syndrome (CFS): this test is useful in assessing subtle irregularities of pituitary-adrenal activity. Nineteen CFS subjects (diagnosed by CDC criteria) and 10 healthy subjects were examined. We demonstrated that 1 microg ACTH significantly elevates DHEA levels, with no difference in output between CFS and healthy subjects. The DHEA/cortisol ratio decreased in response to ACTH stimulation in healthy subjects but not in the CFS cohort. We suggest this divergence of response between the two groups represents an imbalance in the relative synthetic pathways of the CFS group which, if present chronically and if comparable to daily stressors, may manifest itself as an inappropriate response to stress. This difference may be important in either the genesis or propagation of the syndrome.


Assuntos
Hormônio Adrenocorticotrópico/administração & dosagem , Desidroepiandrosterona/metabolismo , Síndrome de Fadiga Crônica/metabolismo , Hidrocortisona/metabolismo , Adulto , Análise de Variância , Estudos de Casos e Controles , Desidroepiandrosterona/sangue , Relação Dose-Resposta a Droga , Síndrome de Fadiga Crônica/sangue , Síndrome de Fadiga Crônica/diagnóstico , Feminino , Humanos , Hidrocortisona/sangue , Sistema Hipotálamo-Hipofisário/metabolismo , Masculino , Sistema Hipófise-Suprarrenal/metabolismo , Valor Preditivo dos Testes
7.
Clin Endocrinol (Oxf) ; 51(5): 653-8, 1999 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-10594528

RESUMO

OBJECTIVE: Desmopressin (DDAVP) is a synthetic analogue of AVP, the companion regulator of corticotrophin-releasing hormone (CRH) in the control of ACTH synthesis and release from the pituitary corticotrophs. The body of evidence from human studies suggests that DDAVP alone, unlike AVP, does not bring about ACTH release, although recent evidence suggests idiosyncracies of response in healthy subjects. We examined whether DDAVP exerted any consistent effect on ACTH and cortisol release, and also if this occurred in a dose-dependant manner. DESIGN AND SUBJECTS: A total of 18 subjects participated in the study. Saline, 5 microg, 10 microg and 15 microg DDAVP were administered as an intravenous bolus at 1300 h; 5, 7, 18 and 8 subjects, respectively, participated in each arm of the study. Plasma ACTH and cortisol responses were measured over a 120-minutes period. RESULTS: Significant between group comparisons were demonstrated for both ACTH (P < 0.05) and cortisol responses (P < 0. 005) measured as maximum increment from baseline. The ACTH response to 5, 10 and 15 microg DDAVP was significantly greater than saline at all three doses, whilst maximal responses were seen at 10 microg. The cortisol responses to 10 and 15 microg DDAVP doses, but not 5 microg, were significantly greater than following saline. 11/18 subjects were deemed 'responders' following 10microg DDAVP on the basis of both ACTH and cortisol output. CONCLUSIONS: This data suggests that DDAVP is capable of stimulating ACTH and cortisol release when administered alone as a bolus in over 50% of healthy subjects. This is in contrast to much of the extant literature. The mode of administration may be pertinent to this effect. This finding has implications for the recent focus on DDAVP as a diagnostic tool in disorders such as Cushing's Disease.


Assuntos
Hormônio Adrenocorticotrópico/sangue , Desamino Arginina Vasopressina , Hidrocortisona/sangue , Fármacos Renais , Adulto , Análise de Variância , Área Sob a Curva , Relação Dose-Resposta a Droga , Método Duplo-Cego , Esquema de Medicação , Feminino , Humanos , Masculino
8.
Psychoneuroendocrinology ; 24(7): 759-68, 1999 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-10451910

RESUMO

No inclusive or satisfactory biomedical explanation for chronic fatigue syndrome (CFS) has as yet been forwarded. Recent research suggests that a dysregulated hypothalamic-pituitary-adrenal axis (HPA) may be contributory, and in particular that there may be diminished forward drive and adrenal under-stimulation. In this preliminary study we wished to examine a cohort of CFS patients in whom evidence for such hypofunctioning was found. Our aim was to establish whether these patients had altered adrenal gland size. Patients were recruited from a fatigue clinic. Those who fulfilled the Centre for Disease Control and Prevention (CDC) criteria underwent a 1 microgram adrenocorticotropin (ACTH) stimulation test, a test of adrenal gland functioning. Eight subjects (five females, three males) with a subnormal response to this test underwent a computer tomography (CT) adrenal gland assessment. Measurements were compared with those from a group of 55 healthy subjects. The right and left adrenal gland bodies were reduced by over 50% in the CFS subjects indicative of significant adrenal atrophy in a group of CFS patients with abnormal endocrine parameters. This is the first study to use imaging methods to measure adrenal gland size in CFS. It is a limitation of this study that a selected CFS sample was employed. A future larger study would optimally employ an unselected cohort of CFS patients. This study has implications not only for the elucidation of CFS pathophysiology, but also for possible therapeutic strategies.


Assuntos
Glândulas Suprarrenais/diagnóstico por imagem , Síndrome de Fadiga Crônica/diagnóstico por imagem , Tomografia Computadorizada por Raios X , Glândulas Suprarrenais/patologia , Glândulas Suprarrenais/fisiopatologia , Hormônio Adrenocorticotrópico , Adulto , Atrofia , Síndrome de Fadiga Crônica/fisiopatologia , Feminino , Humanos , Hidrocortisona/sangue , Sistema Hipotálamo-Hipofisário/fisiopatologia , Masculino , Pessoa de Meia-Idade , Sistema Hipófise-Suprarrenal/fisiopatologia
9.
J Affect Disord ; 53(3): 263-8, 1999 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10404712

RESUMO

BACKGROUND: Endogenous opioid peptides inhibit the hypothalamic-pituitary-adrenal (HPA) axis by influencing the release of hypothalamic corticotropin releasing factors. This study examines whether increased activity of the HPA axis in major depression is associated with reduced opioid tone. METHODS: We measured the adrenocorticotropin (ACTH) and cortisol responses to an intravenous bolus of naloxone 0.125 microg/kg in 13 depressed outpatients and 13 healthy volunteers. RESULTS: The mean cortisol response was significantly reduced (P<0.05), and the ACTH response was also non-significantly reduced in the depressed subjects. CONCLUSIONS: These findings imply that the degree of inhibitory endogenous opioid tone is reduced in depression. Various mechanisms for the finding are discussed, including possible alteration in the function of alpha-adrenergic pathways. CLINICAL IMPLICATIONS: Reduced endogenous opioid tone may explain why some depressed individuals self-medicate with opiates, and depression is associated with opiate withdrawal. Opioid pathways may have a role in the mechanism of action of antidepressant drugs, and may be of relevance in the development of novel antidepressants. LIMITATIONS OF THE STUDY: The sample size was small, leading to a failure of the difference of the basal cortisol levels and also the delta ACTH between the groups to reach statistical significance.


Assuntos
Hormônio Adrenocorticotrópico/metabolismo , Transtorno Depressivo/metabolismo , Hidrocortisona/metabolismo , Naloxona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Adulto , Transtorno Depressivo/psicologia , Feminino , Humanos , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Injeções Intravenosas , Masculino , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Método Simples-Cego
10.
J Affect Disord ; 54(1-2): 129-37, 1999 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-10403156

RESUMO

BACKGROUND: Hyperactivity and hypoactivity of the HPA have been forwarded as of pathophysiological relevance in major depressive disorder and chronic fatigue syndrome (CFS), respectively. METHODS: This study examines cortisol levels in the two disorders, and also assesses levels of the adrenal androgens, dehydroepiandrosterone (DHEA) and its sulphate derivative (DHEA-S), and 17-alpha-hydroxyprogesterone; 15 subjects with CFS diagnosed according to CDC criteria, 15 subjects with DSM III-R major depression and 11 healthy subjects were compared. RESULTS: DHEA and DHEA-S levels were significantly lower in the CFS compared to the healthy group; DHEA-S levels, but not DHEA, were lower in the depressives; cortisol and 17-alpha-hydroxyprogesterone did not differ between the three groups. CONCLUSIONS: A potential role for DHEA, both therapeutically and as a diagnostic tool, in CFS, is suggested.


Assuntos
Desidroepiandrosterona/sangue , Transtorno Depressivo Maior/sangue , Síndrome de Fadiga Crônica/sangue , Hidrocortisona/sangue , Adulto , Feminino , Nível de Saúde , Humanos , Masculino , Índice de Gravidade de Doença
11.
J Clin Endocrinol Metab ; 84(6): 2238-40, 1999 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10372738

RESUMO

Major depression is associated with significant disturbance in hypothalamic-pituitary-adrenal axis functioning, including blunted release of ACTH in response to CRH infusion. Eight melancholic depressives and eight matched healthy comparison subjects underwent, in random order, the following challenges: placebo, CRH, CRH + DDAVP. Blood for ACTH and cortisol estimation was drawn at -15, 0, 15, 30, 45, 60, 90, and 120 min. A blunted release of ACTH, in response to CRH challenge, was observed in depression (P < 0.01), whereas maximal cortisol responses in both groups were similar, despite elevated baseline levels in depression (P < 0.05). The combined CRH/DDAVP infusion produced similar ACTH and cortisol release in both groups. These results suggest that melancholic depression is associated with enhanced pituitary vasopressinergic responsivity.


Assuntos
Hormônio Adrenocorticotrópico/sangue , Hormônio Liberador da Corticotropina/farmacologia , Desamino Arginina Vasopressina/farmacologia , Transtorno Depressivo/metabolismo , Vasopressinas/fisiologia , Adulto , Feminino , Humanos , Hidrocortisona/sangue , Masculino , Pessoa de Meia-Idade , Método Simples-Cego
12.
Biol Psychiatry ; 45(11): 1447-54, 1999 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-10356627

RESUMO

BACKGROUND: Corticotropin-releasing hormone (CRH) and vasopressin (VP) are the two principal neuropeptide regulators of the hypothalamic-pituitary-adrenal axis in man, with VP serving to augment CRH-induced adrenocorticotropic hormone (ACTH) release. Unlike VP, desmopressin (DDAVP), which is a synthetic analogue of VP, when administered alone, has not been shown in healthy subjects to have consistent ACTH-releasing properties. It has been suggested that chronic fatigue syndrome (CFS), characterized by profound fatigue and a constellation of other symptoms, may be caused by a central deficiency of CRH. METHODS: We administered 100 micrograms ovine CRH (oCRH) and 10 micrograms DDAVP, both alone and in combination, to a group of subjects with CFS, and to a group of healthy volunteers. Our aim was to establish the effect of DDAVP on CRH-induced ACTH release in these two groups. RESULTS: The delta-ACTH responses to oCRH were attenuated in the CFS (21.0 +/- 4.5 ng/L) compared to the control subjects (57.8 +/- 11.0 ng/L; t = 3.2, df = 21, p < .005). The delta-cortisol responses were also reduced in the CFS (157.6 +/- 40.7 nmol/L) compared to the healthy subjects (303.5 +/- 20.9 nmol/L; t = 3.1, df = 21, p < .01). The delta-ACTH and delta-cortisol responses to DDAVP alone did not differ between the two groups. On administration of both CRH and DDAVP no response differences between the two groups for either ACTH (p = .3) or cortisol output (p = .87) were established. Comparing the ACTH and cortisol responses to CRH and CRH/DDAVP in only those individuals from each group who had both tests, the cortisol output to the combination was significantly greater in the CFS compared to the healthy group. The ACTH output was also increased in the former group, though this was not significant. CONCLUSIONS: DDAVP augments CRH-mediated pituitary-adrenal responsivity in healthy subjects and in patients with CFS. That DDAVP was capable of normalizing the pituitary-adrenal response to oCRH in the CFS group suggests there may be increased vasopressinergic responsivity of the anterior pituitary in CFS and/or that DDAVP may be exerting an effect at an adrenal level.


Assuntos
Hormônio Liberador da Corticotropina , Desamino Arginina Vasopressina , Síndrome de Fadiga Crônica/fisiopatologia , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Fármacos Renais , Hormônio Adrenocorticotrópico/sangue , Hormônio Adrenocorticotrópico/efeitos dos fármacos , Adulto , Análise de Variância , Área Sob a Curva , Estudos de Casos e Controles , Distribuição de Qui-Quadrado , Hormônio Liberador da Corticotropina/efeitos dos fármacos , Interações Medicamentosas , Síndrome de Fadiga Crônica/tratamento farmacológico , Feminino , Humanos , Hidrocortisona/sangue , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Masculino
14.
Clin Endocrinol (Oxf) ; 48(6): 733-7, 1998 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-9713562

RESUMO

OBJECTIVE: A number of dynamic tests of the hypothalamic-pituitary-adrenal axis provide evidence for a mild central adrenal insufficiency in chronic fatigue syndrome (CFS). The 1 microgram adrenocorticotropin (ACTH) test has been proposed to be more sensitive than the standard 250 micrograms ACTH test in the detection of subtle pituitary-adrenal hypofunctioning. We aimed to establish whether the 1 microgram ACTH test would support such a dysregulation in CFS, and also, given the relative novelty of this test in clinical practice and the uncertainty with regard to appropriate cut-off values for normality, to compare our healthy volunteer data with those of previous studies. PATIENTS AND DESIGN: Twenty subjects with CFS, diagnosed according to Centres for Disease Control and Prevention criteria, were compared with 20 healthy volunteer subjects. All participants underwent a 1 microgram ACTH test beginning at 1400 h. Plasma samples for cortisol estimation were drawn at 0, +30 and +40 min. RESULTS: Baseline cortisol values did not differ between CFS patients and healthy subjects. The delta cortisol (maximum increment from baseline) value was significantly lower in the CFS than the volunteer group (P < 0.05). Comparison of the +30 min cortisol values revealed no significant differences. Using an incremental cortisol of > 250 nmol/l as an arbitrary cutoff point, two (10%) of the healthy subjects and nine (45%) of the CFS subjects failed the test on this basis (chi 2 = 4.3, df = 38, P < 0.05). CONCLUSIONS: This study provides further evidence for a subtle pituitary-adrenal insufficiency in subjects with chronic fatigue syndrome compared to healthy volunteers. Disparities between our healthy volunteer data and those of other groups using the 1 microgram ACTH test suggest that the test may not be as reliable as previously indicated.


Assuntos
Hormônio Adrenocorticotrópico , Síndrome de Fadiga Crônica/fisiopatologia , Hidrocortisona/sangue , Sistema Hipófise-Suprarrenal/fisiopatologia , Adulto , Esquema de Medicação , Síndrome de Fadiga Crônica/sangue , Feminino , Humanos , Masculino , Valor Preditivo dos Testes
15.
Acta Psychiatr Scand ; 97(6): 450-7, 1998 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-9669518

RESUMO

Hypofunctioning of the pituitary-adrenal axis has been suggested as the pathophysiological basis for chronic fatigue syndrome (CFS). Blunted adrenocorticotropin (ACTH) responses but normal cortisol responses to exogenous corticotropin-releasing hormone (CRH), the main regulator of this axis, have been previously demonstrated in CFS patients, some of whom had a comorbid psychiatric disorder. We wished to re-examine CRH activation of this axis in CFS patients free from concurrent psychiatric illness. A sample of 14 patients with CDC-diagnosed CFS were compared with 14 healthy volunteers. ACTH and cortisol responses were measured following the administration of 100 microg ovine CRH. Basal ACTH and cortisol values did not differ between the two groups. The release of ACTH was significantly attenuated in the CFS group (P < 0.005), as was the release of cortisol (P < 0.05). The blunted response of ACTH to exogenous CRH stimulation may be due to an abnormality in CRH levels with a resultant alteration in pituitary CRH receptor sensitivity, or it may reflect a dysregulation of vasopressin or other factors involved in HPA regulation. A diminished output of neurotrophic ACTH, causing a reduced adrenocortical secretory reserve, inadequately compensated for by adrenoceptor upregulation, may explain the reduced cortisol production demonstrated in this study.


Assuntos
Hormônio Adrenocorticotrópico/metabolismo , Hormônio Liberador da Corticotropina , Síndrome de Fadiga Crônica/metabolismo , Hidrocortisona/metabolismo , Sistema Hipófise-Suprarrenal/metabolismo , Adulto , Análise de Variância , Estudos de Casos e Controles , Distribuição de Qui-Quadrado , Feminino , Humanos , Sistema Hipotálamo-Hipofisário/metabolismo , Masculino , Sistema Hipófise-Suprarrenal/efeitos dos fármacos
16.
Life Sci ; 62(22): 1985-98, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-9627097

RESUMO

The role of arginine vasopressin (AVPNP) in the control of adrenocorticotropic hormone (ACTH) secretion is explored, and in particular, its involvement in various stress response paradigms which may be of relevance in our understanding of the pathophysiology of depression. VP is released from two sites in the hypothalamus; the parvicellular division of the paraventricular nucleus (PVN), where corticotropin releasing hormone (CRH) is also formed, and from the magnocellular neurons of the supraoptic nucleus (SON) and the PVN. The intricate interaction with CRH, the other main ACTH secretagogue, and with glucocorticoids, the inhibitory feedback component of hypothalamic-pituitary-adrenal-axis (HPA) activity, is outlined. That VP plays an important role in the stress response is now beyond doubt. Examination of the impact of psychological stressors on the differential expression of VP and CRH at a hypothalamic and pituitary level has been facilitated by advances in molecular biological techniques. Of importance has been the cloning of the V1b receptor gene, the receptor at which AVP is active in the anterior pituitary. Chronic stress paradigms, associated with HPA hyperresponsiveness, and ACTH release following a novel superimposed stress, have been found with relative consistency to show a shift in the CRH:AVP ratio. This may relate to differing feedback sensitivity of AVP to glucocorticoid feedback restraint and the greater responsivity of AVP over CRH to chronic stimulatory stress input. Evidence for functionally distinct pools of ACTH releasing corticotropes, and the finding that AVP levels more closely correlate with ACTH levels than do CRH levels, suggest a more dynamic role for AVP in activity of the stress axis, and a primarily permissive function for CRH. The renewed interest in the role of VP in HPA axis activity may have important implications for furthering our understanding of psychiatric conditions such as depression, where significant dysregulation of this axis is seen. Elevated baseline cortisol, dexamethasone non-suppression and blunted CRH/ACTH release have been consistently documented. The possible contribution of VP to this hyperactivity, despite its known synergy with CRH, has been largely neglected. In animal models there is clear evidence that chronic psychological stressors increase the ratio of AVP to CRH production. Psychosocial stressors are intrinsically linked with depressive illness. The finding of elevated levels of AVP in postmortem studies of depressives and the lowering of CSF AVP levels by antidepressants, raises the question of the precise role of AVP in the overactivity of the HPA in depression, a finding that is currently attributed to overdrive of its HPA regulatory companion, CRH.


Assuntos
Arginina Vasopressina/fisiologia , Depressão/fisiopatologia , Sistema Hipotálamo-Hipofisário/fisiopatologia , Sistema Hipófise-Suprarrenal/fisiopatologia , Hormônio Adrenocorticotrópico/metabolismo , Animais , Hormônio Liberador da Corticotropina/metabolismo , Humanos , Sistema Hipotálamo-Hipofisário/metabolismo , Sistema Hipófise-Suprarrenal/metabolismo , Transdução de Sinais
17.
Psychol Med ; 28(2): 285-93, 1998 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-9572086

RESUMO

BACKGROUND: Opioidergic pathways have an inhibitory regulatory influence on the hypothalamic-pituitary-adrenal axis (HPA) in man. Previous studies have suggested impairment of pituitary-adrenal activation in chronic fatigue syndrome (CFS). We, therefore, decided to investigate the extent of opioid inhibition of HPA activity in CFS as a possible explanation for the reputed HPA hypofunctioning in patients with CFS. METHOD: Thirteen patients with CFS, diagnosed according to CDC criteria, were compared with thirteen healthy subjects. Adrenocorticotropin (ACTH) and cortisol (CORT) responses were measured following the administration of the opiate antagonist naloxone. RESULTS: Baseline ACTH and cortisol levels did not differ between the two groups. The release of ACTH (but not cortisol) was significantly blunted in the CFS subjects compared with controls. CONCLUSIONS: Naloxone mediated activation of the HPA is attenuated in CFS. Excessive opioid inhibition of the HPA is thus an unlikely explanation for the HPA dysregulation in this disorder.


Assuntos
Síndrome de Fadiga Crônica/fisiopatologia , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Naloxona , Antagonistas de Entorpecentes , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Hormônio Adrenocorticotrópico/sangue , Adulto , Área Sob a Curva , Estudos de Casos e Controles , Distribuição de Qui-Quadrado , Feminino , Humanos , Hidrocortisona/sangue , Masculino , Pessoa de Meia-Idade , Vias Neurais/fisiopatologia , Receptores Opioides/fisiologia
18.
J Affect Disord ; 47(1-3): 49-54, 1998 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-9476743

RESUMO

Urinary free cortisol excretion (UFC) was compared in 21 patients with chronic fatigue syndrome (CFS), in 10 melancholic depressives and in 15 healthy controls. Patients with depression had UFC values which were significantly higher than healthy comparison subjects, whereas UFC excretion of CFS patients was significantly lower than the comparison group. These findings are in keeping with currently held hypotheses of hyperactivity and hypoactivity of the hypothalamic-pituitary-adrenal (HPA) axis in depression and chronic fatigue syndrome respectively. Five of the 21 CFS patients had a co-morbid depressive illness. This sub-group retained the profile of UFC excretion of those with CFS alone, suggesting a different pathophysiological basis for depressive symptoms in CFS.


Assuntos
Transtorno Depressivo/urina , Síndrome de Fadiga Crônica/urina , Hidrocortisona/urina , Adulto , Idoso , Comorbidade , Transtorno Depressivo/epidemiologia , Transtorno Depressivo/fisiopatologia , Síndrome de Fadiga Crônica/epidemiologia , Síndrome de Fadiga Crônica/fisiopatologia , Feminino , Humanos , Sistema Hipotálamo-Hipofisário/fisiopatologia , Masculino , Pessoa de Meia-Idade , Sistema Hipófise-Suprarrenal/fisiopatologia
19.
Psychoneuroendocrinology ; 22(4): 261-7, 1997 May.
Artigo em Inglês | MEDLINE | ID: mdl-9226729

RESUMO

We examined 5HT1a-mediated ACTH release in patients with chronic fatigue syndrome (CFS) using a between-subjects design. Patients attending a specialist outpatient clinic for CFS, who fulfilled CDC criteria, together with age- and sex-matched healthy comparison subjects, were recruited. Subjects had a cannula inserted in a forearm vein at 0830 h and were allowed to relax until 0900 h, when baseline bloods for ACTH and cortisol were drawn. They were then given ipsapirone 20 mg PO and further blood for hormone estimation was taken at +30, +60, +90, +120 and +180 min. Baseline ACTH and cortisol levels did not differ between the two groups. Release of ACTH (but not cortisol) in response to ipsapirone challenge was significantly blunted in patients with CFS. We conclude that serotonergic activation of the hypothalamic-pituitary-adrenal axis is defective in CFS. This defect may be of pathophysiological significance.


Assuntos
Síndrome de Fadiga Crônica/fisiopatologia , Sistema Hipotálamo-Hipofisário/fisiopatologia , Sistema Hipófise-Suprarrenal/fisiopatologia , Serotonina/fisiologia , Hormônio Adrenocorticotrópico/sangue , Adulto , Síndrome de Fadiga Crônica/diagnóstico , Síndrome de Fadiga Crônica/psicologia , Feminino , Humanos , Hidrocortisona/sangue , Masculino , Pessoa de Meia-Idade , Pirimidinas , Receptores de Serotonina/fisiologia , Agonistas do Receptor de Serotonina
20.
Artigo em Inglês | MEDLINE | ID: mdl-8983335

RESUMO

The role of cortisol in influencing spontaneous and 5HT mediated prolactin release was investigated in 17 healthy male subjects who took part in 3 separate studies. Five of the subjects were treated for 24 h with metyrapone (the 11 beta-hydroxylase inhibitor which prevents the conversion of 11-deoxycortisol to cortisol) on one occasion and placebo for 24 h on another. On both test occasions their spontaneous prolactin was monitored before they underwent serotonergic-stimulated prolactin release using D-fenfluramine (30 mg). Treatment with metyrapone enhanced the spontaneous nocturnal prolactin surge and also the prolactin response to D-fenfluramine. Six of the subjects were treated for 24 h with hydrocortisone on one occasion or placebo on the other. With hydrocortisone treatment no nocturnal increase in prolactin was observed and the response to D-fenfluramine challenge was attenuated. To determine whether the influence of cortisol on prolactin release is at a pituitary or supra-pituitary site 6 subjects were tested with thyrotropin releasing hormone (TRH) which acts directly on the pituitary to bring about prolactin release. They were each tested twice, following either metyrapone or placebo treatment. The rise following metyrapone was significantly greater than that seen following placebo. The results suggest that cortisol influences both spontaneous and 5HT stimulated PRL release, probably acting at a pituitary level.


Assuntos
Anti-Inflamatórios/farmacologia , Hidrocortisona/farmacologia , Metirapona/farmacologia , Prolactina/metabolismo , Adulto , Análise de Variância , Anti-Inflamatórios/sangue , Ritmo Circadiano , Fenfluramina , Humanos , Hidrocortisona/sangue , Masculino , Prolactina/sangue , Serotoninérgicos , Hormônio Liberador de Tireotropina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA